Identifying older adults at increased risk of medication-related readmission to hospital within 30 days of discharge: development and validation of a risk assessment tool

Maria Glans 1,2, Thomas Gerardus Hendrik Kempen,3,4 Ulf Jakobsson,1 Annika Kragh Ekstam,5 Åsa Bondesson,1,6 Patrik Midlöv 1

ABSTRACT

Objective Developing and validating a risk assessment tool aiming to identify older adults (≥65 years) at increased risk of possibly medication-related readmission to hospital within 30 days of discharge.

Design Retrospective cohort study.

Setting The risk score was developed using data from a hospital in southern Sweden and validated using data from four hospitals in the mid-eastern part of Sweden.

Participants The development cohort (n=720) was admitted to hospital during 2017, whereas the validation cohort (n=892) was admitted during 2017–2018.

Measures The risk assessment tool aims to predict possibly medication-related readmission to hospital within 30 days of discharge. Variables known at first admission and individually associated with possibly medication-related readmission were used in development. The included variables were assigned points, and Youden’s index was used to decide a threshold score. The risk score was calculated for all individuals in both cohorts. Area under the receiver operating characteristic (ROC) curve (c-index) was used to measure the discrimination of the developed risk score. Sensitivity, specificity and positive and negative predictive values were calculated using cross-tabulation.

Results The developed risk assessment tool, the Hospitalisations, Own home, Medications, and Emergency admission (HOME) Score, had a c-index of 0.69 in the development cohort and 0.65 in the validation cohort. It showed sensitivity 76%, specificity 54%, positive predictive value 29% and negative predictive value 90% at the threshold score in the development cohort.

Conclusion The HOME Score can be used to identify older adults (≥65 years) at increased risk of possibly medication-related readmission to hospital within 30 days of discharge. The tool is easy to use and includes variables available in electronic health records at admission, thus making it possible to implement risk-reducing activities during the hospital stay as well as at discharge and in transitions of care. Further studies are needed to investigate the clinical usefulness of the HOME Score as well as the benefits of implemented activities.

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ In this study, a risk assessment tool—the Hospitalisations, Own home, Medications, and Emergency admission (HOME) Score—aiming to identify older adults (≥65 years) at increased risk of possibly medication-related readmission to hospital within 30 days of discharge was developed and externally validated.

⇒ Only variables available in the electronic health records at admission to hospital were included in the risk assessment tool.

⇒ Possibly medication-related readmissions were identified using the same tool. Assessment Tool for Identifying Hospital Admissions Related to Medication (AT-HARM10), in both the development cohort and the validation cohort.

⇒ Further validations of the HOME Score are needed in order to establish its clinical usefulness in different departments as well as in other countries.

INTRODUCTION

Readmission to hospital is common, especially in older adults, where almost 20% of discharges result in a readmission within 30 days.1–3 In older adults, hospitalisation can be associated with a risk of complications such as exposure to infections, a rise in adverse events, episodes of confusion and accidental injury through falls.4–5 As readmissions are not only a risk for the individual patient but also for the health economy,6 many countries have set goals to decrease the frequency of readmission within 30 days of discharge.67

According to previous research,8–10 a relatively large proportion of readmissions to hospital, in older adults, is medication related. However, the amount differs greatly between studies as shown in a systematic review by El Morabet et al.8 In this study, the amount of medication-related readmission reported
was 3%–64% with a median of 21% (IQR 14%–23%). These differences are due to a number of factors, one being the use of different definitions of ‘medication related’ between studies.8 While some studies measure readmissions related to adverse drug reactions, adverse drug events or drug–drug reactions others measure readmissions related to medication-related problems, thus including all the above-mentioned problems.8

Many medication-related readmissions may be possible to prevent, even though the proportion deemed preventable also differs between studies,8 again, due to differences in methods used. According to previous research, preventive measures should aim to improve medication use as well as transitions of care11 12 and are best performed by combining several minor activities into concepts.12 13 These activities should preferably include interdisciplinary actions during the hospital stay and at discharge12 as well as collaboration between hospital, primary and municipal care in transitions of care.14

To effectively implement interventions, healthcare personnel need to be able to identify patients at increased risk of medication-related readmission. This could preferably be done by using a risk assessment tool or risk score.15 Some risk assessment tools linked to medication-related readmission have been developed.16 17 The Prospective study to develop a model to stratify the RIsk of Medication-related harm in hospitalised Elderly patients (PRIME) tool, developed by Parekh et al.,16 identifies older adults at increased risk of medication-related harm requiring healthcare use within 8 weeks of discharge, while the decision support tool developed by Olson et al.17 predicts the risk of readmission in older adults using high-risk medication regimens. None of these tools have been validated in an external population or tested in a setting other than the one where it was developed.

To our knowledge, there is no risk assessment tool available that specifically aims to identify older adults at increased risk of possibly medication-related readmission to hospital within 30 days of discharge. If such a tool was available, interventions aiming to prevent readmission could be implemented based on the risk in the individual patient.15 This could make it possible to not only increase patient safety but also relocate some resources to other areas within healthcare.

**OBJECTIVE**

The aim of this study was to develop and validate a risk assessment tool that can be used to identify older adults (≥65 years) at increased risk of possibly medication-related readmission to hospital within 30 days of discharge.

**METHODS**

This study is reported according to the transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) statement.15

**Setting**

Sweden is divided into 21 regions and 290 municipalities.18 Primary and hospital care is provided by the regions, while nursing care, in the community or in nursing homes, is provided by the local municipalities. When it comes to planning patient care after hospital discharge, hospital and municipal care are expected to collaborate.19

According to Swedish directives and general advice,20 a medication reconciliation should be performed by the attending physician when patients aged 75 years and older using five medications or more are admitted to hospital. In performing the medication reconciliation, the attending physician can be supported by other healthcare personnel, for example, a clinical pharmacist.

If medication-related problems are present, the medication reconciliation should be followed by a medication review which could or could not be performed interdisciplinary (ie, involving a geriatrician or a clinical pharmacist). Unfortunately, adherence to these directives seems generally low21 with only about 15% of patients aged 75 years and older receiving a medication reconciliation and/or medication review during their hospital stay.21

**Patient and public involvement**

Patients or the public were not involved in this study.

**Development of the risk assessment tool**

The risk assessment tool was developed using anonymised data and results from our previously published retrospective studies,10 22 where further details on the population and methods of data collection can be found.

**Study sample and procedure**

The study was conducted at Kristianstad hospital, which is an emergency hospital with 255 beds situated in Skåne county in the south of Sweden. The study population, which is further referred to as the development cohort, consisted of randomly selected patients (n=720), aged 65 years and older, who had been admitted to Kristianstad hospital for at least 24 hours in 2017. Patients were admitted to one of the following departments: internal medicine, infectious disease, general surgery, orthopaedics or ear/nose/throat. The study group (n=360) was readmitted to any department in the hospital, for at least 24 hours, within 30 days of discharge, while the comparison group (n=360) was not. Variables were collected from electronic health records in an unblinded yet standardised and objective manner, as previously described.22

In total, 143 of 360 readmissions (39.7%) were assessed as being possibly medication related.16 Assessments were made using the Assessment Tool for identifying Hospital Admissions Related to Medication (AT-HARM10), a validated tool to distinguish between admissions that are possibly and unlikely medication related.23 With AT-HARM10 a possibly medication-related (re)admission is defined as being either caused by or significantly contributed to by a medication-related problem and

a medication-related problem is defined according to Strand et al., that is, as an ‘undesirable patient experience that involves medication therapy and that actually or potentially interferes with desired patient outcomes’. This means that medication-related problems involve not only adverse drug reactions or adverse drug events but also problems such as inappropriate prescribing, non-compliance and problems related to over-the-counter medications. For further details on AT-HARM10, see online supplemental appendix 1.

Preliminary assessments, made by the first author in an unblinded fashion, were reviewed, revised and finalised by an experienced geriatrician. For further details on the assessment process, see our previous publication.

Through multiple logistic regression analysis (stepwise backward), individual risk factors associated with all-cause readmission, possibly medication-related readmission, and unlikely medication-related readmission within 30 days of discharge were identified, as described in our previous publications.

Variables included

The risk assessment tool was developed using variables identified by comparing patients with a possibly medication-related readmission (n=143) with those that did not have a possibly medication-related readmission (n=577) (ie, patients with an unlikely medication-related readmission (n=217) and patients not readmitted (n=360)). Only variables known at first admission to hospital were included in the development of the risk assessment tool.

Variables shown to be associated with possibly medication-related readmission, through multiple logistic regression analysis, were chosen to be included in the final risk assessment tool. For continuous variables, categorical variables were created based on comparisons between groups.

Data analysis

Based on the odds ratios (ORs) of the individual variables in the final multiple logistic regression model, suitable weighting and scoring were decided on for each of the included variables. A risk score, which summarised the points assigned to each of the variables included, was calculated for all the included individuals. Finally, a new logistic regression analysis was performed with possibly medication-related readmission as the dependent variable and the risk score as the test variable, saving the probabilities for further analysis. To estimate the quality of the model Hosmer-Lemeshow goodness of fit was calculated as well as Nagelkerke R².

A ROC curve was plotted using the saved probabilities and the area under the ROC curve (c-index) was calculated giving a measure of how well the tool predicts possibly medication-related readmission.

To decide on a suitable threshold value in the risk assessment tool Youden’s index (J= sensitivity+specificity–1) was calculated for all steps in the risk score. Cross-tabulation was used to calculate sensitivity, specificity and positive and negative predictive values as well as to identify the number of correctly predicted patients.

Statistical analyses were performed using IBM SPSS Statistics V.27.

External validation of the risk score

To check the predictive ability of the risk score, as well as its precision and usefulness in other populations, we performed an external validation using data from the Medication Reviews Bridging Healthcare (MedBridge) trial.

Study sample and procedure

The MedBridge trial was a randomised clinical trial conducted at four hospitals (Uppsala, Gävle, Västerås and Enköping) in the mid-eastern part of Sweden. The aim of the trial was to study the effects of hospital-based medication reviews including postdischarge follow-up on the use of healthcare resources in older adults (265 years), compared with hospital-based reviews and usual care only.

Included participants were admitted to a medical ward at one of the four included hospitals for at least 24 hours within the time frame 6 February 2017 to 19 October 2018. Out of the 2637 patients included in the trial, 1745 were included in 1 of the 2 medication review groups, and 892 patients were included in the group receiving usual care. Outcomes measured in the trial included readmission to hospital within 30 days of discharge and possibly medication-related readmission, as assessed with AT-HARM10. For further details on the population and methods of data collection used in the MedBridge trial, see Kempen et al’s study.

To make sure the medication review interventions in the MedBridge trial could not affect the result of the validation, the MedBridge control group, that is, the 892 patients receiving usual care, was chosen to create the validation cohort in which the developed risk assessment tool was validated. In the validation cohort (n=892), 132 patients were readmitted within 30 days of discharge and 54 of these readmissions (40.9%) were assessed as being possibly medication related.

Data analysis

A multiple logistic regression analysis with the variables included in the risk assessment tool was performed in the validation cohort, comparing patients with a possibly medication-related readmission (n=54) and those that did not have a possibly medication-related readmission (n=838) (ie, those with an unlikely medication-related readmission (n=78) and those that were not readmitted within 30 days of discharge (n=760)). To estimate the quality of the model, Hosmer-Lemeshow goodness of fit was calculated as well as Nagelkerke R².

The risk score was calculated for each of the individuals in the validation cohort, and a new logistic regression analysis was performed with possibly medication-related readmission as the dependent variable and the risk score
as the test variable. Probabilities were saved and used to plot a ROC curve where the c-index was calculated giving an estimate of the predictive ability of the risk assessment tool in this external population.

Cross-tabulation was used at each of the steps in the risk score to calculate sensitivity, specificity and positive and negative predictive values. Furthermore, the number of correctly predicted patients was identified.

Statistical analysis was performed using IBM SPSS Statistics V.27.

RESULTS
Development of the risk assessment tool

Variables included

The following variables were shown to be individually associated with possibly medication-related readmission and chosen to be included in the risk assessment tool: number of hospitalisations within the last 12 months, living in own home with home care, living in own home alone, number of medications at admission and emergency admission.

For the continuous variables, number of hospitalisations within the last 12 months and number of medications at admission, categorical variables were created based on comparisons of means and medians between groups.

The mean number of hospitalisations in patients with a possibly medication-related readmission was 1.94 and the median was 2. The mean number in the comparison group (including patients not readmitted and those with a readmission unlikely related to medications) was 1.67 and the median was 1. Hence, the categorical variable was set as hospitalisations within the last 12 months ≥ 2.

The mean number of medications at first admission to hospital in patients with a possibly medication-related readmission and in the comparison group (ie, patients not readmitted and those with a readmission unlikely related to medications) was 10.30 and 8.09, respectively, and the median was 10 and 7, respectively. Both the categorical variable, number of medications at admission ≥ 5 and number of medications at admission ≥ 10, were tested in the multiple logistic regression model. Both variables showed similar odds ratios (2.20 with number of medications ≥ 5 and 1.99 with number of medications ≥ 10) and both had significant p values (0.005 with number of medications ≥ 5 and < 0.001 with number of medications ≥ 10). Finally, we chose to use the categorical variable, number of medications at admission ≥ 5, in the final model (table 1).

Developing the risk score

The ORs of the variables that were individually associated with possibly medication-related readmission were used for assigning points to each of the included variables. Hence, since the OR for emergency admission was about double the size of the other included variables, emergency admission was assigned two points whereas the other variables were assigned one point each, giving a maximum score of six points. The resultant 0–6 points risk score, shown in figure 1, was named the Hospitalisations, Own home, Medications, and Emergency admission (HOME) Score.

The model showed fair calibration with a Hosmer-Lemeshow goodness-of-fit p value of 1.000 and Nagelkerke $R^2$ of 0.117. The calculated area under the risk score ROC curve (c-index) was 0.69 (95% CI 0.64 to 0.74).

Youden’s Index was calculated for each step in the risk score using the coordinates in the ROC curve (table 2). A suitable threshold value would be where Youden’s Index is closest to 1, in this case at a score of 4 or 5.

A score of ≥ 4 points was finally chosen as the threshold score. The choice was based on the desire to identify as many patients at increased risk of possibly medication-related readmission as possible, that is, sensitivity rather than specificity should be as high as possible. At the threshold score (≥ 4 points), sensitivity was 76%, specificity 53%, positive predictive value 29% and negative predictive value 90% (table 3). The number of correctly predicted patients was 108 (out of 143).

External validation of the risk assessment tool

In the validation cohort only the variable hospitalisations within the last 12 months ≥ 2 was shown to be individually

<table>
<thead>
<tr>
<th>Variable</th>
<th>OR</th>
<th>95% CI for OR</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>1.00</td>
<td>0.98 to 1.03</td>
<td>0.986</td>
</tr>
<tr>
<td>Sex</td>
<td>1.02</td>
<td>0.69 to 1.50</td>
<td>0.939</td>
</tr>
<tr>
<td>Emergency admission</td>
<td>4.03</td>
<td>1.42 to 11.45</td>
<td>0.009</td>
</tr>
<tr>
<td>Hospitalisations in the last 12 months ≥ 2</td>
<td>1.53</td>
<td>1.04 to 2.27</td>
<td>0.033</td>
</tr>
<tr>
<td>Medications at admission ≥ 5</td>
<td>2.20</td>
<td>1.27 to 3.80</td>
<td>0.005</td>
</tr>
<tr>
<td>Living in own home with home care</td>
<td>1.84</td>
<td>1.17 to 2.89</td>
<td>0.009</td>
</tr>
<tr>
<td>Living in own home alone</td>
<td>1.59</td>
<td>1.06 to 2.39</td>
<td>0.026</td>
</tr>
</tbody>
</table>

Hosmer-Lemeshow goodness-of-fit test p value: 0.802. Nagelkerke $R^2$: 0.113.

Significant p values are indicated in bold.

*Adjusted for gender and age.
associated with possibly medication-related readmission (table 4).

Logistic regression analysis in the validation cohort, with possibly medication-related readmission as the dependent variable and HOME Score as the test variable, showed fair calibration with a Hosmer-Lemeshow goodness-of-fit p value of 1.000 and Nagelkerke $R^2$ of 0.051.

The c-index of the HOME Score was 0.65 (95% CI 0.57 to 0.72, p value<0.001) in the validation cohort. The risk score, with the cut-off point set at ≥4 points, showed a non-significant difference between groups (p value 0.051). At this threshold score (≥4), sensitivity was 63%, specificity 51%, positive predictive value 8% and negative predictive value 96% (table 3). The number of correctly predicted patients was 34 (out of 54). With the cut-off point set at ≥5 points, there was a significant difference between groups (p value<0.001). Sensitivity was 43%, specificity 80%, positive predictive value 12% and negative predictive value 96%. The number of correctly predicted patients was 23 (out of 54) (table 3).

**DISCUSSION**

The risk assessment tool developed in this study, the HOME Score, is the first externally validated risk assessment tool that can be used to identify older adults (≥65 years) at increased risk of possibly medication-related readmission within 30 days of discharge. The HOME Score was fairly discriminative of possibly medication-related readmission and showed fair calibration in development as well as in external validation. The tool is easy to use and includes variables that should be readily available in the electronic health records at admission, thus making it possible to implement risk-reducing

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Youden’s Index calculated for each step in the risk score in order to find a suitable threshold value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Score</td>
<td>Sensitivity</td>
</tr>
<tr>
<td>0</td>
<td>1.000</td>
</tr>
<tr>
<td>1</td>
<td>1.000</td>
</tr>
<tr>
<td>2</td>
<td>0.951</td>
</tr>
<tr>
<td>3</td>
<td>0.937</td>
</tr>
<tr>
<td>4</td>
<td>0.755</td>
</tr>
<tr>
<td>5</td>
<td>0.413</td>
</tr>
<tr>
<td>6</td>
<td>0.147</td>
</tr>
</tbody>
</table>
Table 3  Diagnostic testing of the HOME Score in the development and validation cohorts

<table>
<thead>
<tr>
<th></th>
<th>Development cohort</th>
<th>Validation cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample size</td>
<td>720</td>
<td>892</td>
</tr>
<tr>
<td>Readmission within 30 days of discharge, n (%)</td>
<td>360 (50)</td>
<td>132 (15)</td>
</tr>
<tr>
<td>Possibly medication-related readmission, n (%)</td>
<td>143 (40)</td>
<td>54 (41)</td>
</tr>
<tr>
<td>Unlikely medication-related readmission, n (%)</td>
<td>217 (60)</td>
<td>78 (59)</td>
</tr>
<tr>
<td>Area under ROC curve (SE)</td>
<td>0.69 (0.02)</td>
<td>0.65 (0.04)</td>
</tr>
<tr>
<td>95% CI</td>
<td>0.64 to 0.74</td>
<td>0.57 to 0.72</td>
</tr>
<tr>
<td>Patient distribution</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HOME Score&lt;4, n (%)</td>
<td>343 (48)</td>
<td>443 (50)</td>
</tr>
<tr>
<td>HOME Score≥4, n (%)</td>
<td>377 (52)</td>
<td>447 (50)</td>
</tr>
<tr>
<td>Patients with possibly medication-related readmission</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HOME Score&lt;4, n (%)</td>
<td>35 (10)</td>
<td>20 (5)</td>
</tr>
<tr>
<td>HOME Score≥4, n (%)</td>
<td>108 (29)</td>
<td>34 (8)</td>
</tr>
<tr>
<td>At HOME Score≥4:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sensitivity, %</td>
<td>76</td>
<td>63</td>
</tr>
<tr>
<td>Specificity, %</td>
<td>53</td>
<td>51</td>
</tr>
<tr>
<td>Positive predictive value, %</td>
<td>29</td>
<td>8</td>
</tr>
<tr>
<td>Negative predictive value, %</td>
<td>90</td>
<td>96</td>
</tr>
<tr>
<td>Number of correctly predicted patients, n</td>
<td>108</td>
<td>34</td>
</tr>
<tr>
<td>At HOME Score≥5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sensitivity, %</td>
<td>41</td>
<td>43</td>
</tr>
<tr>
<td>Specificity, %</td>
<td>83</td>
<td>80</td>
</tr>
<tr>
<td>Positive predictive value, %</td>
<td>38</td>
<td>12</td>
</tr>
<tr>
<td>Negative predictive value, %</td>
<td>85</td>
<td>96</td>
</tr>
<tr>
<td>Number of correctly predicted patients, n</td>
<td>59</td>
<td>23</td>
</tr>
</tbody>
</table>

HOME, Hospitalisations, Own home, Medications, and Emergency admission; ROC, receiver operating characteristic.

Table 4  Comparison* of variables between groups in the development and validation cohort

<table>
<thead>
<tr>
<th>Predictor</th>
<th>Development cohort</th>
<th>Validation cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PMRR (n=143)</td>
<td>Comparison group† (n=577)</td>
</tr>
<tr>
<td>Hospitalisations within the last 12 months≥2, %</td>
<td>52</td>
<td>36</td>
</tr>
<tr>
<td>Living in own home, with home care, %</td>
<td>37</td>
<td>18</td>
</tr>
<tr>
<td>Living in own home, alone, %</td>
<td>53</td>
<td>37</td>
</tr>
<tr>
<td>Number of medications at admission≥5, %</td>
<td>87</td>
<td>71</td>
</tr>
<tr>
<td>Emergency admission, %</td>
<td>97</td>
<td>89</td>
</tr>
</tbody>
</table>

Significant p values (p<0.05) are indicated in bold.
*A χ² test was used for analysis in all cases.
†Comparison group=patients not readmitted and patients with an unlikely medication-related readmission.
PMRR, possibly medication-related readmission.
activities during the hospital stay as well as at discharge and in transitions of care.

Comparisons to other studies
There have not yet, to our knowledge, been any risk assessment tools developed that are directly comparable to the HOME Score. However, there are several tools that can be used to identify patients at increased risk of all-cause readmission to hospital within 30 days of discharge, such as the Hemoglobin at discharge, from an Oncology service, Sodium level at discharge, Procedure during the index admission (any ICD-9-CM-coded procedure), Index Type of admission (nonelective vs elective), number of Admissions during the last 12 months and Length of stay (HOSPITAL) Score, the Length of stay, Acuity of the admission, Comorbidity of the patient (the total Charlson Comorbidity Index) and Emergency department attendances in the last 6 months (LACE) Index and the Potentially Avoidable Readmission-Risk (PAR-Risk) Score. Even though the PAR-Risk Score focuses on medications as a risk factor for potentially avoidable hospital readmissions, it does not specifically predict medication-related readmissions. There are, however, a few risk assessment tools related to medication-related healthcare use after discharge, such as the PRIME tool and the decision support tool developed by Olson et al. None of the above-mentioned tools solely includes factors that are known already at admission as does the HOME Score.

The PRIME tool, developed by Parekh et al., identifies older patients (≥65 years) at increased risk of medication-related harm requiring healthcare use within 8 weeks of discharge from hospital. The tool was derived in a multi-centre, prospective cohort study in the UK. In total, 818 patients discharged from 5 UK teaching hospitals between 2013 and 2015 were included. The PRIME tool was internally validated using bootstrapping and the c-index was 0.69 before and 0.66 after validation. Hence, compared with the PRIME tool, the HOME Score has a similar predictive ability with a c-index of 0.69 in the development cohort and 0.65 in the validation cohort.

With the PRIME tool, healthcare use after discharge includes not only hospital readmissions but also other healthcare use such as visits to the emergency department, in-person or telephone consultations with a general practitioner, or visits to outpatient clinics. This means that the PRIME tool predicts healthcare use in broader sense than does the HOME Score. Further, medication-related harm in the PRIME tool is defined as adverse drug reactions and harm arising from non-adherence only while the HOME Score defines medication-related problems more broadly, also including problems such as inappropriate prescribing and problems related to over-the-counter medications (see online supplemental appendix 1).

Variables included in the model
The variables included in the HOME Score were identified in our previous studies where we identified risk factors for all-cause readmission, possibly medication-related readmission and unlikely medication-related readmission within 30 days of discharge, in patients 65 years and older. We chose to solely include variables known already at admission since research suggests that the successful reduction of possibly medication-related readmission demands the implementation of actions during the hospital stay as well as at discharge and in transitions of care. In order to do this, patients at increased risk of possibly medication-related readmission need to be identified already at admission. Hence, the HOME Score has an advantage compared with previously developed tools such as the PRIME tool, which include factors not known until discharge.

Hospitalisations within the last 12 months
The number of previous hospitalisations is a measure of disease burden and the fact that readmitted patients are more ill does not really come as a surprise since this has been shown previously. In a Swedish study from 2022, Naseer et al. showed that emergency department visits in older adults are significantly associated with several variables indicating disease burden, such as number of chronic diseases, number of primary care visits, number of emergency department visits, polypharmacy and receipt of home care.

Naseer et al. have also shown that prior healthcare use is associated with emergency department revisits within 30 days, in older adults. Similarly, we have identified previous healthcare use as a risk factor for possibly medication-related readmissions within 30 days of discharge which is why this factor was included in the HOME Score. Prior healthcare use has also been indicated as a risk factor for all-cause readmission and the factor is included, in some form, in the HOSPITAL Score, the LACE Index and the PAR-Risk Score.

Living in own home with home care and/or alone
Living in your own home alone is included as a variable in the HOME Score as well as in the PRIME tool. Living arrangements have been previously indicated as risk factors for readmission in several studies. In 2016, Olson et al. identified an increased risk of readmission in older men living in their own home with only their adult children as caregivers. Further, Gruneir et al. have shown that patients using high-risk medications have an 80% increased risk of readmission within 30 days if discharged to their own home as opposed to a nursing home. However, Naseer et al. did not find living alone to be explanatory of emergency department revisits in older adults. They did, on the other hand, find the receipt of home care to be significantly associated with emergency department revisits in one of the two Swedish regions studied. Similarly, Dahlberg et al. have shown that living at home with home care is significantly associated with unplanned (emergency) admission to hospital.

When it comes to readmission to hospital, we have previously shown that living in the community with home
care is a risk factor for all-cause readmission⁵ and in this study, further analyses showed that it is also associated with possibly medication-related readmission. This factor is not, to our knowledge, found in other assessment tools aiming to identify all-cause readmission or possibly medication-related readmission. However, it is part of several comprehensive geriatric assessment tools aiming to identify vulnerability and frailty.⁶⁻⁷ Such comprehensive geriatric assessment tools have also been shown to be predictive of all-cause readmission to hospital within 30 days and 60 days of discharge, in older adults.

**Number of medications at admission ≥5**

Polypharmacy is a commonly indicated risk factor for medication-related problems in older adults.⁹ Polypharmacy, in itself, is not necessarily a bad thing, but with age comes physiological changes that affect the pharmacokinetics and pharmacodynamics of medications. This leads to increased sensitivity which, in turn, leads to an increased risk of medication-related problems.⁶ The presence of polypharmacy and medication-related problems can lead to increased healthcare use and, as shown in this study, to possibly medication-related readmissions. Hence, polypharmacy was included in the HOME Score. Similarly, the number of medications used is included as a risk factor in the PRIME tool as well as in the decision support tool predicting elderly patients’ risk of readmission based on their high-risk medication regimens, developed by Olson et al.¹⁶

**Emergency admission**

Emergency admission, as opposed to planned admission, has been indicated as a risk factor for 30-day readmission in several studies, including ours, and the factor is included in both the HOSPITAL Score and the LACE Index.⁸⁻¹⁰

In the study by Dahlberg et al., the only social factor significantly associated with unplanned hospital admission was living at home with home care. Furthermore, in our previous study, we showed that older adults with a possibly medication-related readmission who lived alone were more often readmitted due to an unsustainable home situation than those living with someone. Since living with home care and living alone are also indicated as risk factors for all-cause and possibly medication-related readmissions, this indicates that these readmitted older adults need closer supervision after discharge. At the very least, they need better planning before discharge. To achieve this, the collaboration among hospital, primary and municipal care needs to improve.¹²⁻¹⁴

**Implications for clinical use**

Healthcare involving multimorbid older adults is complex and integrating care across disciplines, as well as working together in interdisciplinary teams, is important to achieve safe and effective healthcare.¹¹⁻¹⁴ Improving medication use as well as transitions of care has been shown to be important factors when aiming to reduce the frequency of medication-related readmissions.¹¹⁻¹² Including clinical pharmacists in the interdisciplinary team, to help with medication reconciliation and medication review as well as information transfer and follow-up regarding medications and medication changes, can support this.¹²⁻¹⁴⁻¹⁷⁻¹⁹⁻²¹⁻²³ The HOME Score can be used to find the patients in most need of this support.

Even though the positive predictive value of the HOME Score is quite low (29% in the development cohort and 8% in the validation cohort), it could be useful in clinical practice, especially considering the negative predictive value. Among the 50% of older adults identified as at low risk of medication-related readmission, 90% of patients in the development cohort and 96% in the validation cohort were indeed not readmitted due to medication-related problems. Hence, using the HOME Score, healthcare personnel can easily rule out 50% of patients 65 years and older who are not at increased risk of medication-related readmission. This can be done already at admission to hospital, and in doing so, the efficiency and effectiveness of preventive actions aiming to improve medication use and transitions of care can probably improve. This can possibly, in turn, lead to an increase in patient safety as well as benefits to the health economy. Further studies are needed to test these hypotheses.

**Strengths and limitations**

According to the TRIPOD statement an internal validation should always be performed when developing a prediction model, which was not done in this study. This choice was based on the fact that an external validation, using a geographically separate population, was performed. We considered this to be sufficient as clinical prediction models are always in need of further validation studies, as performance differs between locations, settings and over time. Hence, this is just a first edition of the HOME Score and further studies are needed to test its clinical usefulness and to keep it up to date.

The HOME Score was developed using data from a retrospective study performed in a population admitted to a single Swedish hospital. This could limit its generalisability, which is why an external validation was carried out using data from four other hospitals in another part of Sweden. The tool’s predictive ability was withstand, suggesting that it can be used when aiming to identify patients at increased risk of possibly medication-related readmission in Sweden. However, further studies are needed to assess the international validity of the HOME Score as well as its validity in other populations within Sweden. As stated previously, this is merely a first edition of the HOME Score and further studies are needed to test its clinical usefulness and to keep it updated.

We chose to include the categorical variable number of medications at admission, in the final risk score even though the median number of medications was 10,30 in patients with a possibly medication-related readmission and 8,09 in the comparison group. This choice was based on the Swedish directives and general advice, stating...
that a medication reconciliation should be performed in admitted patients taking five medications or more, but it may have weakened the prediction model. This is one of the aspects that should be examined when further validating the HOME Score and investigating its clinical usefulness.

The population used in developing the HOME Score was tailored for the identification of risk factors for all-cause readmission and possibly medication-related readmission.10,22 This led to a larger proportion of readmitted patients in the development cohort (50%) compared with the proportion in the validation cohort (15%), the proportion of 30-day readmissions in the validation cohort being closer to that reported in previous studies.1-3 This could be considered a weakness.

The tool AT-HARM1023 was used by clinical pharmacists in both the development10 and validation cohort25 26 in order to assess whether 30-day readmissions were possibly or unlikely medication-related. This is a strength as the same definition of medication-related readmission was used in both populations. However, even though the tool has been validated,25 26 the assessments are implicit, and the result depends on the person conducting them. This could be considered a weakness. The fact that the amount of possibly medication-related readmissions was almost the same in the development and validation cohort (40% in the development cohort and 41% in the validation cohort) indicates that this may not be a big issue.

In the development cohort, included patients were admitted to medical as well as surgical departments whereas patients in the validation cohort were admitted solely to medical wards. This could have affected the results and further validations of the HOME Score are needed in order to establish its clinical usefulness in different departments as well as in other countries.

Conclusion

The HOME Score can be used to identify older adults at increased risk of possibly medication-related readmission within 30 days of discharge. The tool is easy to use and includes variables that should be readily available in electronic health records at admission, thus making it possible to implement risk-reducing activities during the hospital stay as well as at discharge and in transitions of care. These activities could possibly help increase patient safety as well as be beneficial to the health economy but care. These activities could possibly help increase patient hospital stay as well as at discharge and in transitions of possible to implement risk-

Supplemental material

This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

ORCID iDs

Maria Glans http://orcid.org/0000-0003-1329-7977

Patrik Midlöv http://orcid.org/0000-0002-5871-8731

REFERENCES


